Merck & Co Inc (MRK) Stock Price, Trades & News

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).

Financial Strength

5/10

Name	Current	Vs Industry
Cash-To-Debt	0.12
Equity-to-Asset	0.36
Debt-to-Equity	1.07
Debt-to-EBITDA	4.51
Interest Coverage	5.74
Piotroski F-Score	4/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	3.95	Distress Grey Safe
Beneish M-Score	-2.66	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

9/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	3.6
	3-Year EBITDA Growth Rate	10.4
	3-Year EPS without NRI Growth Rate	6.3
	3-Year FCF Growth Rate	-5.2
	3-Year Book Growth Rate	5.5
	Future 3-5Y Total Revenue Growth Rate Estimate	6.47

Momentum Rank

1/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	47.85
	9-Day RSI	52.34
	14-Day RSI	54.42
	3-1 Month Momentum %	10.92
	6-1 Month Momentum %	5.45
	12-1 Month Momentum %	53.1

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	1.3
	Quick Ratio	1.06
	Cash Ratio	0.21
	Days Inventory	131.34
	Days Sales Outstanding	64.42
	Days Payable	81.49

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	2.58
	Dividend Payout Ratio	1.05
	3-Year Dividend Growth Rate	5.4
	Forward Dividend Yield %	2.62
	5-Year Yield-on-Cost %	3.4
	3-Year Average Share Buyback Ratio	0.8
	Shareholder Yield %	1.97

Profitability Rank

8/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	72.97
	Operating Margin %	10.49
	Net Margin %	4.77
	EBITDA Margin %	16.36
	FCF Margin %	24.13
	OCF Margin %	29.99
	ROE %	6.41
	ROA %	2.53
	ROIC %	4.18
	3-Year ROIIC %	14.23
	ROC (Joel Greenblatt) %	25.44
	ROCE %	7.38
	Years of Profitability over Past 10-Year	10
	Moat Score	8
	Tariff Resilience Score	7

GF Value Rank

7/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	104.74
	Forward PE Ratio	41.77
	PE Ratio without NRI	40.79
	Shiller PE Ratio	32.25
	Price-to-Owner-Earnings	60.18
	PEG Ratio	2.58
	PS Ratio	4.84
	PB Ratio	7.05
	Price-to-Free-Cash-Flow	23.17
	Price-to-Operating-Cash-Flow	18.24
	EV-to-EBIT	47.7
	EV-to-Forward-EBIT	33.83
	EV-to-EBITDA	25.46
	EV-to-Forward-EBITDA	22.6
	EV-to-Revenue	5.51
	EV-to-Forward-Revenue	5.37
	EV-to-FCF	22.84
	Price-to-GF-Value	1.1
	Price-to-Projected-FCF	2.01
	Price-to-Median-PS-Value	1.12
	Price-to-Peter-Lynch-Fair-Value	1.72
	Earnings Yield (Greenblatt) %	2.1
	FCF Yield %	4.97
	Forward Rate of Return (Yacktman) %	17.81

Financials (Next Earnings Date:2026-10-29)

Annual Quarterly TTM

MRK's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Gurus Latest Trades with NYSE:MRK

No Available Data

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Merck & Co Inc Executives

Details

GF Value™: $119.37

MRK

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 10 Medium warning signs with MRK. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil $)	66,569
	EPS (TTM) ($)	1.25
	Beta	-0.0212
	3-Year Sharpe Ratio	0.21
	3-Year Sortino Ratio	0.36
	Volatility %	27.29
	14-Day RSI	54.42
	14-Day ATR ($)	3.31503
	20-Day SMA ($)	127.8605
	12-1 Month Momentum %	53.1
	52-Week Range ($)	77.58 - 135.05
	Shares Outstanding (Mil)	2,469.82

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	4
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Merck & Co Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Merck & Co Inc Stock Events

Financials Calendars

Event	Date	Price ($)
Fourth quarter earnings conference call for 2026	2027-02-02 09:00	In 176 days
Fourth quarter earnings results for 2026	2027-02-02	In 175 days
Third quarter earnings conference call for 2026	2026-10-29	In 79 days
Third quarter earnings results for 2026	2026-10-29	In 79 days
USD 0.850000 Cash Dividend	2026-09-15	In 35 days
Second quarter earnings conference call for 2026	2026-08-04 09:00	127.77 (-1.62%)
Second quarter earnings results for 2026	2026-08-04	127.77 (-1.62%)
USD 0.850000 Cash Dividend	2026-06-15	119.05 (-2.02%)
Goldman Sachs 47th Annual Global Healthcare Conference	2026-06-09 11:20	119.52 (-1.10%)
Jefferies Global Healthcare Conference in New York	2026-06-04 10:30	114.70 (-0.65%)

Show

Entries

Merck & Co Inc Frequently Asked Questions

What is Merck & Co Inc(MRK)'s stock price today?

The current price of MRK is $130.92. The 52 week high of MRK is $135.05 and 52 week low is $77.58.

When is next earnings date of Merck & Co Inc(MRK)?

The next earnings date of Merck & Co Inc(MRK) is 2026-10-29.

Does Merck & Co Inc(MRK) pay dividends? If so, how much?

The Dividend Yield % of Merck & Co Inc(MRK) is 2.58% (As of Today), Highest Dividend Payout Ratio of Merck & Co Inc(MRK) was 1.96. The lowest was 0.37. And the median was 0.47. The Forward Dividend Yield % of Merck & Co Inc(MRK) is 2.62%. For more information regarding to dividend, please check our Dividend Page.

Guru Commentaries on NYSE:MRK

FPA Queens Road Value Fund, Q2 2024 Commentary

Carillon Eagle Growth & Income Fund, Q1 2024 Fund Letter

Andrew Hill, Andrew Hill Investment Advisors, Q1 2023 Fund Letter

Press Release

	Subject	Date
	U.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk	2026-08-06
	Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline	2026-08-04
	Merck Announces Fourth-Quarter 2026 Dividend	2026-07-29
	Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development	2026-07-24
	Merck's LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia	2026-07-16
	Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026	2026-07-15
	KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR)	2026-07-15
	FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults	2026-07-10
	Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4	2026-07-01
	Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV	2026-06-29

10/Page

Articles on Merck & Co Inc

MRK

Merck & Co Inc (MRK) EVP & President of Merck Animal Health Richard Deluca Sells 6,050 Shares

2 hours ago

MRK

Immunotherapy's Biggest Blind Spot Is a $7 Billion Market. Silexion May Have a Way In (NASDAQ: SLXN)

5 hours ago

MRK

Merck & Co Inc (MRK) EVP Chirfi Guindo Sells 15,000 Shares

3 days ago

MRK

MRK Looks 7.8% Overvalued on GF Value™

4 days ago

MRK

U.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk

5 days ago

Headlines

Aug 10, 2026

Trump executive order set to make major changes to childhood vaccines schedule

Seeking Alpha • 1:59pm

Aug 08, 2026

Earnings Scorecard: 95% of healthcare firms deliver EPS wins this week

Seeking Alpha • 10:15am

Aug 06, 2026

4 stocks to watch on Thursday: U, MRK, DDOG, and FISV

Seeking Alpha • 7:35am

Aug 04, 2026

Merck projects 2026 EPS of $2.66-$2.76 as it raises revenue view to $66.3B-$67.3B following Terns deal

Seeking Alpha • 12:42pm

Merck in charts: Keytruda remains the growth engine in Q2 as Gardasil rebounds

Seeking Alpha • 5:50am

Merck Non-GAAP EPS of -$0.13 beats by $0.13, revenue of $16.61B beats by $240M

Seeking Alpha • 5:32am

Aug 03, 2026

Pfizer, Merck Q2 preview: New growth bets face legacy headwinds

Seeking Alpha • 11:35am

Jul 31, 2026

Dividend Roundup: Wells Fargo, Merck, Citigroup, Carnival Corp, and more

Seeking Alpha • 7:53am

Jul 30, 2026

BMS granted FDA review for label expansion of Merck-partnered anemia therapy

Seeking Alpha • 12:26pm

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.